Abstract
In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.
| Original language | English |
|---|---|
| Pages (from-to) | 1263-1272 |
| Number of pages | 10 |
| Journal | Chemotherapy |
| Volume | 40 |
| Issue number | 10 |
| DOIs | |
| Publication status | Published - 1992 |
| Externally published | Yes |
Fingerprint
Keywords
- flucytosine
ASJC Scopus subject areas
- Oncology
- Pharmacology
- Drug Discovery
- Pharmacology (medical)
- Infectious Diseases
Cite this
Dose finding studies on flucytosine in patients with fungi in their urine. / Uno, Satoshi; Takenaka, Tadasu; Nishitani, Yoshio; Hayashi, Toshihide; Hata, Kazuhiro; Ono, Noriaki; Tsugawa, Masaya; Kumon, Hiromi; Ohmori, Hiroyuki; Nanba, Katsuichi; Kondoh, Yoshikatu; Ohashi, Teruhisa; Irie, Shin; Kaneshige, Tetuzou; Kawahara, Hiroyuki; Tanaka, Hiroyoshi; Yamamoto, Shouichi; Takada, Motoyoshi; Yamada, Daisuke; Asai, Toshihiko; Katayama, Yasuhiro; Akaeda, Teruaki; Mizuno, Akihiro; Ishito, Noritaka; Akazawa, Nobuyuki; Kishi, Mikio; Nasu, Ryouji; Mitsuhata, Naoki; Hayata, Shunji; Nasu, Yasutomo; Yamamoto, Toshiki; Akagi, Takafumi; Tanimura, Masanobu; Kataoka, Seiichi; Fujita, Yukitoshi; Hirai, Yoshikazu; Kanemasa, Yasuhiro; Saitoh, Yasuichi.
In: Chemotherapy, Vol. 40, No. 10, 1992, p. 1263-1272.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Dose finding studies on flucytosine in patients with fungi in their urine
AU - Uno, Satoshi
AU - Takenaka, Tadasu
AU - Nishitani, Yoshio
AU - Hayashi, Toshihide
AU - Hata, Kazuhiro
AU - Ono, Noriaki
AU - Tsugawa, Masaya
AU - Kumon, Hiromi
AU - Ohmori, Hiroyuki
AU - Nanba, Katsuichi
AU - Kondoh, Yoshikatu
AU - Ohashi, Teruhisa
AU - Irie, Shin
AU - Kaneshige, Tetuzou
AU - Kawahara, Hiroyuki
AU - Tanaka, Hiroyoshi
AU - Yamamoto, Shouichi
AU - Takada, Motoyoshi
AU - Yamada, Daisuke
AU - Asai, Toshihiko
AU - Katayama, Yasuhiro
AU - Akaeda, Teruaki
AU - Mizuno, Akihiro
AU - Ishito, Noritaka
AU - Akazawa, Nobuyuki
AU - Kishi, Mikio
AU - Nasu, Ryouji
AU - Mitsuhata, Naoki
AU - Hayata, Shunji
AU - Nasu, Yasutomo
AU - Yamamoto, Toshiki
AU - Akagi, Takafumi
AU - Tanimura, Masanobu
AU - Kataoka, Seiichi
AU - Fujita, Yukitoshi
AU - Hirai, Yoshikazu
AU - Kanemasa, Yasuhiro
AU - Saitoh, Yasuichi
PY - 1992
Y1 - 1992
N2 - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.
AB - In order to determine the optimal dose of flucytosine (5-FC) in the treatment of fungi in the urine, we performed a dose-finding study. The patients were randomly assigned to receive 5-FC 2 g or 3 g (potency) for 7–14 days by the envelope method. Overall clinical efficacy was evaluated based on the criteria of the Japanese U TI Committee, with slight modification. The efficacy rates were 65.5% (19/29) for the 2 g group and 71.4% (15/21) for the 3g group, and the respective mycological eradication rates were 76.7% and 77.3%, with no statistically significant difference. Clinical adverse reactions were observed in 2.6% and 6.5% of the patients, respectively, with no statistically significant difference. Consequently, we believe that the optimal daily dose of flucytosine is 2 g (1 g b.i.d.) in the treatment of fungi in the urine.
KW - flucytosine
UR - http://www.scopus.com/inward/record.url?scp=0026564024&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0026564024&partnerID=8YFLogxK
U2 - 10.11250/chemotherapy1953.40.1263
DO - 10.11250/chemotherapy1953.40.1263
M3 - Article
AN - SCOPUS:0026564024
VL - 40
SP - 1263
EP - 1272
JO - Chemotherapy
JF - Chemotherapy
SN - 0009-3165
IS - 10
ER -